A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities.

Roisin Connolly, Vered Stearns

Research output: Contribution to journalArticle

Abstract

Neoadjuvant therapy may provide advantages to some women with primary operable breast cancer. Compared to the administration of the same regimen in the adjuvant setting, neoadjuvant chemotherapy does not improve survival outcomes, but may provide other benefits. Neoadjuvant therapy is associated with improved rates of breast-conserving therapy, may offer prognostic information, and enables assessment of in vive response to therapy. Women who achieve a pathologic complete response following neoadjuvant therapy are expected to have a superior outcome compared to those with extensive residual disease. The neoadjuvant setting has been an attractive area of research for identifying new effective treatment strategies while minimizing treatment-related adverse events, studying drug mechanisms of action, and developing clinically applicable prognostic and predictive biomarkers in an attempt to individualize therapy. In the primary operable setting, it is of great importance to define treatment goals, to select proper candidates for the approach, to assess baseline tumor characteristics, and to provide optimal multidisciplinary monitoring during and following the neoadjuvant therapy.

Original languageEnglish (US)
Pages (from-to)135-143
Number of pages9
JournalOncology
Volume24
Issue number2
StatePublished - Feb 2010

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Breast
Biomarkers
Drug Therapy
Survival
Research
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities. / Connolly, Roisin; Stearns, Vered.

In: Oncology, Vol. 24, No. 2, 02.2010, p. 135-143.

Research output: Contribution to journalArticle

@article{9fc217a22e5b4475af746dee9e38070b,
title = "A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities.",
abstract = "Neoadjuvant therapy may provide advantages to some women with primary operable breast cancer. Compared to the administration of the same regimen in the adjuvant setting, neoadjuvant chemotherapy does not improve survival outcomes, but may provide other benefits. Neoadjuvant therapy is associated with improved rates of breast-conserving therapy, may offer prognostic information, and enables assessment of in vive response to therapy. Women who achieve a pathologic complete response following neoadjuvant therapy are expected to have a superior outcome compared to those with extensive residual disease. The neoadjuvant setting has been an attractive area of research for identifying new effective treatment strategies while minimizing treatment-related adverse events, studying drug mechanisms of action, and developing clinically applicable prognostic and predictive biomarkers in an attempt to individualize therapy. In the primary operable setting, it is of great importance to define treatment goals, to select proper candidates for the approach, to assess baseline tumor characteristics, and to provide optimal multidisciplinary monitoring during and following the neoadjuvant therapy.",
author = "Roisin Connolly and Vered Stearns",
year = "2010",
month = "2",
language = "English (US)",
volume = "24",
pages = "135--143",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities.

AU - Connolly, Roisin

AU - Stearns, Vered

PY - 2010/2

Y1 - 2010/2

N2 - Neoadjuvant therapy may provide advantages to some women with primary operable breast cancer. Compared to the administration of the same regimen in the adjuvant setting, neoadjuvant chemotherapy does not improve survival outcomes, but may provide other benefits. Neoadjuvant therapy is associated with improved rates of breast-conserving therapy, may offer prognostic information, and enables assessment of in vive response to therapy. Women who achieve a pathologic complete response following neoadjuvant therapy are expected to have a superior outcome compared to those with extensive residual disease. The neoadjuvant setting has been an attractive area of research for identifying new effective treatment strategies while minimizing treatment-related adverse events, studying drug mechanisms of action, and developing clinically applicable prognostic and predictive biomarkers in an attempt to individualize therapy. In the primary operable setting, it is of great importance to define treatment goals, to select proper candidates for the approach, to assess baseline tumor characteristics, and to provide optimal multidisciplinary monitoring during and following the neoadjuvant therapy.

AB - Neoadjuvant therapy may provide advantages to some women with primary operable breast cancer. Compared to the administration of the same regimen in the adjuvant setting, neoadjuvant chemotherapy does not improve survival outcomes, but may provide other benefits. Neoadjuvant therapy is associated with improved rates of breast-conserving therapy, may offer prognostic information, and enables assessment of in vive response to therapy. Women who achieve a pathologic complete response following neoadjuvant therapy are expected to have a superior outcome compared to those with extensive residual disease. The neoadjuvant setting has been an attractive area of research for identifying new effective treatment strategies while minimizing treatment-related adverse events, studying drug mechanisms of action, and developing clinically applicable prognostic and predictive biomarkers in an attempt to individualize therapy. In the primary operable setting, it is of great importance to define treatment goals, to select proper candidates for the approach, to assess baseline tumor characteristics, and to provide optimal multidisciplinary monitoring during and following the neoadjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=77951234638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951234638&partnerID=8YFLogxK

M3 - Article

C2 - 20361464

VL - 24

SP - 135

EP - 143

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 2

ER -